Brain implants like those being developed by Elon Musk's Neuralink are becoming the latest friction point in the intensifying U.S.-China rivalry in the life sciences. Why it matters: The devices are bringing new hope to patients with strokes, Parkinson's disease and other neurological conditions. And tech billionaires have fueled advances by pouring billions into biotech startups focused on linking the brain with computers. - But a new national security analysis says U.S. development efforts are being overtaken by Beijing's full-court press around manufacturing, data and commercialization. - The consequences could extend beyond health care, affecting U.S. military capabilities and the ability to train the next generation of AI…
AI has an image problem . And one way to fix it is for top companies to dive headlong into health care. Why it matters: Saving the world with AI-designed cures is better than being blamed for ruining the environment or driving up Americans' utility bills. - But even the most advanced AI models can't produce miracle treatments at the moment — and could create serious security risks if they try. - That could set up a fraught debate over the next two or three years about the allocation of resources and whether the benefits of throwing vast amounts of computing capacity into medical research outweigh the costs. Driving the news: The Wall Street Journal reported this month that Anthropic was trying to shore up investor confidence ahead…
Over the past five years, according to the Shapiro administration, researchers and companies in the state have secured more than 10,700 new life science patents, which is the fourth-highest total in the country.
Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it's priming a bigger automation push that's changing the trajectory of early stage pharma research. Why it matters: The TD Cowen survey of 80 biopharma leaders and insiders finds AI is compressing drug developers' preclinical costs and timelines by as much as 70%. - That's fueling demand for cutting-edge software, sequencing tools and computer models that will help churn out more experimental treatments in the next five years. The big picture: AI can't replace scientific intuition. But the way it can streamline the grueling R&D before human testing begins is making computer screens as important a feature of drug design as…
A California company partnering with the Pentagon to develop an antidote for venomous snakebites is in animal trials to gauge the drug’s suitability for humans.
A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline.
Mosquitoes are the deadliest animal in the world, and Google wants to release millions of them in California and Florida. Google's life sciences department breeds mosquitoes, and it believes by releasing more, it can reduce the harmful ones. NewsNation's Nick Smith reports. Start your day with "Morning in America," NewsNation's live three-hour national morning newscast hosted by Markie Martin. Weekdays starting at 6a/5C. #MorningInAmerica NewsNation is your source for fact-based, unbiased news for all Americans.
Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.
Get ready for a biology lesson. Certain plants have extra sets of chromosomes. And it turns out, it's a useful trait for a species facing a dramatic event like climate change.
